Keywords: loss of heterozygosity; tumor suppressor genes; testicular germ cell tumors
Introduction
Testicular germ cell tumors (TGCTs) are the most common tumors in young men.
It is generally accepted that the TGCTs originate from intratubular germ cell neoplasia (ITGCN). Histologically and clinically, TGCTs are classified into seminomas and nonseminomas. About 50% of TGCTs are pure seminomas, and 40% are pure or mixed nonseminomas. The remaining 10% containing both seminoma and nonseminoma components are classified as being nonseminomas according to the WHO 2004 classification system [4] .
Seminomas develop from the sperm-producing germ cells of the testicle. The two main types of seminomatous tumors are classic seminoma and spermatocytic seminoma.
Seminoma is the most common testicular germ cell neoplasm and usually occurs in patients in the fourth decade of life.
There are four main types of nonseminomatous tumors: embryonal carcinoma, yolk sac tumor, immature or mature teratoma and choriocarcinoma. These tumor types are often seen together in various combinations, referred to as mixed TGCTs, which may also include a seminoma component [1] . The undifferentiated stem cells of nonseminomas are termed embryonal carcinoma cells and can differentiate into a broad spectrum of somatic tissues (teratomas) and the extraembryonal derivates: yolk sac tumors and choriocarcinomas [15] . Nonseminoma occurs most frequently between 20 and 40 years of age.
Molecular genetic studies of TGCTs have reported allele loss on chromosomes 1, 3, 5, 9, 11, 12, 13, 17 and 18. However, mutation analyses of candidate tumor suppressor genes such as RB, TP53, WT1, BRCA1, APC, CDH1, MCC, NF2 and DCC have demonstrated only rare alterations, so major TGCT suppressor genes are yet to be identified [10] . To date the exact cellular and molecular mechanisms leading to the neoplastic progression of ITGCN are still not fully understood [13] . Increasing evidence suggests that carcinogenesis must be understood in terms of an accumulation of mutations in regulatory genes, including activation of oncogenes and inactivation or loss of tumor suppressor genes.
APC and E-cadherin proteins are components of the adherens junction, where Ecadherin is bound to β-catenin, which in turn binds to the central part of the APC.
Besides their roles in cellular architecture, the APC and β-catenin play a signaling role as components of the Wnt signal transduction pathway [17] . APC acts as a negative regulator of the Wnt signaling pathway, being a critical component of the β-catenin destruction machinery heading to the proteasome. E-cadherin has a role in Wnt signaling, too; where it acts as an indirect modulator of Wnt signaling. Since it binds to and sequesters cytoplasmic β-catenin, it is involved in the modulation of the signal [16] .
These genes are also implicated in cancer, especially in neoplasms of epithelial origin.
Several studies have suggested that TGCTs express high levels of wild type p53 protein but apparently do not contain p53 mutations [6] , [7] . The p53 pathway responds to a variety of intrinsic and extrinsic stress signals and when activated maintains cellular integrity by inducing cell arrest, senescence or apoptosis. It has been shown that β-catenin and p53 form a negative feedback loop that regulates Wnt signaling. β-catenin induces p53 activation by inducing p14ARF expression, p14ARF inhibits Mdm2 and consequently leads to an accumulation of active p53 [3] .
Nucleoside diphosphate (NDP) kinases, responsible for the synthesis of nucleoside triphosphates and produced by the nm23 genes, are involved in numerous regulatory processes associated with cell growth, differentiation, tumor progression, metastasis and development. Nm23-H1 is overexpressed in solid tumors as compared to normal tissues with a reduced expression correlated with the metastatic potential of some tumors [5] . The immunohistochemically detected expression of both the nm23-H1 and -H2 gene products is not associated with the metastatic status or the invasive status of testicular seminoma [11] .
Our objective was to examine the loss of heterozygosity (LOH) of APC, CDH1 (E-cadherin), p53 and nm23-H1 tumor suppressor genes in 38 TGCTs (17 seminomas and 21 nonseminomas). Gene products of APC, CDH1 and p53 are involved in the Wnt signaling pathway implicated in embryogenesis and cancerogenesis, whereas the role of nm23-H1 protein in the development of TGCTs has not been elucidated. Table 1 .
Materials and Methods

Patients
DNA extraction.
For each specimen, a 20 µm paraffin-embedded section was prepared for DNA extraction. In addition, a 4 µm section was stained with hemalauneosin to identify the tumor and normal tissue areas which were removed separately from the microscopic slide, transferred to microtubes and extracted using QIAamp DNA Mini Kit (Qiagen, Germany).
LOH analysis of APC, p53, CDH1 and nm23-H1 genes. LOH of APC and p53
genes were detected using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method ( Table 2) restriction site in intron 6 of the p53 were examined as previously mentioned [12] .
Analyses of the D16S752 tetranucleotide microsatellite marker linked to CDH1 and M2 dinucleotide microsatellite marker linked to nm23-H1 were carried out by PCR using 5 pmol of each primer (Table 2) , under the APC PCR conditions. Obtained fragments were analyzed on silver-stained 15% polyacrylamide gel. Loss of heterozygosity of CDH1 and nm23-H1 was considered to occur if one out of two alleles (heterozygous samples) of gene markers was missing or significantly reduced in comparison to alleles from adjacent normal tissue.
Results
Genetic studies were performed for the presence of possible allelic losses of APC, p53, CDH1 and nm23-H1 tumor suppressor genes.
First, the RsaI polymorphic site in APC's exon 11 was analyzed. From 38 TGCTs, 29 samples (76%, 13 seminomas and 16 nonseminomas) were informative for this polymorphism. Four (14%) samples: three seminomas (23%) and one nonseminoma (6%) demonstrated LOH (Tables 3 and 4 ). These tumor samples showed either only one band, a 133-bp fragment (Fig. 1) , or two bands (48-bp and 85-bp fragments).
Two polymorphic sites of p53 gene, a Bsh123GI restriction site in exon 4 and a MspI restriction site in intron 6, were used. Analysis of these two markers showed that 30 tumors (79%, 12 seminomas and 18 nonseminomas) were heterozygous for the first polymorphism. Loss of heterozygosity was observed in five (28%) nonseminoma cases as one of the alleles missing in comparison to bands from the adjacent normal testis tissue ( Although we observed moderate levels of allelic losses of p53 and CDH1 genes in nonseminomas, and moderate level of LOH of APC gene in seminomas (Table 4) , there are no statistically significant differences in LOHs between seminomas and nonseminomas found using Fisher's exact test due to the small number of samples.
Discussion
Human tumorigenesis is a multistep process. For some cancers there is considerable knowledge of the molecular events associated with progression from early precursor lesions to metastatic cancer. Although knowledge of the pathogenesis of TGCTs is more limited, a multistep model with the progression from ITGCN to seminoma and then to nonseminoma has been widely proposed. However, the specific gene alteration events that might determine the progression from ITGCN to nonseminoma are ill-defined [10] .
The majority of infantile testis tumors, seminomas and nonseminomas, show a biallelic expression of imprinted genes. These data support the hypothesis that these germ cell tumors originate from an early erased germ cell [15] . If a loss of genomic imprinting affects a tumor suppressor gene, one allele is already inactivated due to the passage through either a male or a female germ line.
Recently, a novel model for examing testicular teratomas has been identified [19] .
This model indicates that Wnt signaling is able to induce teratomas in p53 mutant cells and suggests that a single copy of the p53 gene is sufficient for blocking tumorigenesis in male germ cells.
In the present study, we investigated allelic losses of APC, CDH1, p53 and nm23-H1 genes to elucidate whether LOHs of these genes are linked to a particular phenomenon of the signaling pathway disruption or are a consequence of whole genome instability in view of the high number and variety of chromosome abnormalities, including deletions and rearrangements present in TGCTs [2] .
It is important to mention that we tested more nonseminoma than seminoma samples (17 seminomas and 21 nonseminomas), but only informative (heterozygous) samples were calculated. The number of informative samples for single genetic marker does not differ significantly between two main histological groups of TGCTs (Table 4) .
Exon 4 of the p53 gene is involved in induction of apoptosis, whereas changes in intron 6 are implicated in its expression by protein stabilization. A moderate level (28%) of allelic loss of the p53 in nonseminomas suggests that loss of this gene may contribute to their development. Previously, Peng et al. [18] have observed a LOH of p53 gene in 22% of TGCTs, despite the fact that mutations within the coding region of p53 rarely occur in testis cancer. However, they have not observed the discrepancies between two different markers in the same gene in terms of LOH scoring in seminomas and nonseminomas (20% versus 26%, respectively).
In self-renewing tissues such as colon and testis, the APC protein is thought to modulate the stem cell differentiation by controlling the β-catenin /Tcf-Lef pathway in which APC targets β-catenin for degradation. To date, the function of APC in human testes is unclear [14] . Most mutations of the APC gene are frameshift mutations, however, it is recognised that a number of tumors demonstrated LOH of this gene.
Peng et al. [18] observed that LOH occured in 28% of informative cases at APC gene. However, they did not detect statistically significant differences in LOH of APC, by using two different markers in the same gene, between the seminomas and nonseminomas (31% versus 25%, respectively).
To increase both informativity and sensitivity, we examined the MspI restriction site polymorphism in APC's exon 15, a 550 bp target sequence containing a polymorphic MspI restriction site with restriction to two 250 bp fragments (heterozygous alleles).
However, the PCR amplification of APC's exon 15 was unsuccessful. In general, it is particulary difficult to amplify DNA from paraffin-embedded tissue when the amplified fragment is larger than 300 bp, perhaps due to degradation of the DNA. Therefore, we have not searched for two different markers in the same gene (with the exception of p53, those markers are presented separately), to avoid any influence on the outcome of the results.
E-cadherin has been viewed as a tumor suppressor, mainly by maintaining cellcell adhesion and anchoring β-catenin in a submembranous location [16] . Mutations of CDH1 gene have been found in a number of tumors, but not in testicular cancers.
Although two groups of authors [21] , [9] reported increased expression of CDH1 in nonseminomas compared to seminomas, and Sonne et al. [23] observed increased expression of CDH1 in both seminomas and nonseminomas from pateints with stage II/III disease, Heidenreich et al. [8] proposed a correlation between loss of E-cadherin and lymph node metastases in stage I nonseminomas. However, Honecker et al. [9] have found that neither vascular invasion nor the frequency of metastatic spread correlate with E-cadherin expression.
Interestingly, in our study one seminoma with CDH1 allelic deletion also demonstrated allelic loss of APC's exon 11. Furthermore, one nonseminoma with p53 exon 4 allelic deletion demonstrated LOH of the CDH1 gene (Table 3) . Allelic losses of both CDH1 and p53 genes are more prominent in nonseminomas, which may contribute to their increased genomic instability and invasivness. All LOHs of the p53, except for one, were found in tumors with an embryonal carcinoma component, and all cases of CDH1 LOHs in nonseminoma were found in tumors with a yolk sac tumor component.
Both are highly invasive types of nonseminomas. The majority of CDH1 LOHs were found in T2 and T3 stage tumors, which might be because it is either a late occurence in the tumorigenesis, or it has a role in the invasiveness of these tumors.
Although nm23 proteins are expressed in testis germinal cells, studies on mutations and expression of the nm23-H1 and nm23-H2 genes in TGCTs have failed to establish a significant role in the development of these tumors [22] . In accordance with these findings, we did not find aberrations of nm23-H1 in TGCTs.
In the present study, analysis of allelic losses has shown no common structural genetic alterations in tumor tissues. Different pattern of LOH has been observed between two main histological groups of TGCTs, in agreement with the data published by Rothe et al. [20] . Occurrence of LOHs within two main groups of TGCTs turned out to be either 6-11% or 23-28% for examined gene markers. These LOH rates correspond to cytogenetically normal and abnormal chromosomes, respectively [18] . Although we have not performed cytogenetic analysis, our results suggest that different chromosomal aberrations are present in two main groups of TGCTs. Since we observed neither LOHs of nm23-H1 nor BRCA1 (unpublished results), both located on chromosome 17q, we believe the short arm of chromosome 17 is involved in cytogenetic changes of TGCTs. 21  37  pT1NXMX  EC, ITGCN, S  22  28  pT2NXMX  C, EC, IT, MT  23  17  pT2NXMX  EC, MT  24  34  pT2NXMX  EC  25  19  pT1NXMX  EC, ITGCN, MT, YST  26  39  pT1NXMX  MT, YST  27  21  pT2NXMX  EC, MT, YST  28  23  pT2NXMX  EC, IT, MT  29  22  pT1NXMX  MT, YST  30  25  pT3NXMX  EC  31  45  pT2NXMX  EC, ITGCN, S, YST  32  NK  pT2NXMX  C, EC, ITGCN, S, YST  33  23  pT2NXMX  EC, IT, ITGCN, MT, YST  34  39  pT1NXMX  EC, ITGCN, S, YST  35  24  pT2NXMX  EC, ITGCN, YST  36  30  pT1NXMX  EC, ITGCN, YST  37  36  pT1NXMX  EC, ITGCN, MT, YST  38  58  pT2NXMX EC, ITGCN, YST C-choriocarcinoma; EC-embryonal carcinoma; IT-immature teratoma; ITGCN-intratubular germ cell neoplasia; MT-mature teratoma; S-seminoma; YST-yolk sac tumor; NK-not known Table 2 . The sequences of pairs of primers used in the PCR reaction followed by LOH analysis of CDH1, APC, p53 and nm23-H1 
